Evidence map›Paper›PMID 35274010›Full record

ArticleFrontiers in cardiovascular medicine2022

The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study.

Soo Jin Na, Jong-Chan Youn, Hye Sun Lee, Soyoung Jeon, Hae-Young Lee, Hyun-Jai Cho, Jin-Oh Choi, Eun-Seok Jeon, Sang Eun Lee, Min-Seok Kim and 10 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 1 country.

Soo Jin NaDepartment of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jong-Chan YounDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Hye Sun LeeBiostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, South Korea.
Soyoung JeonBiostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, South Korea.
Hae-Young LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Hyun-Jai ChoDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Jin-Oh ChoiDepartment of Internal Medicine, Sungkyunkwan University College of Medicine, Seoul, South Korea.
Eun-Seok JeonDepartment of Internal Medicine, Sungkyunkwan University College of Medicine, Seoul, South Korea.
Sang Eun LeeDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Min-Seok KimDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Jae-Joong KimDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kyung-Kuk HwangDepartment of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, South Korea.
Myeong-Chan ChoDepartment of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, South Korea.
Shung Chull ChaeDepartment of Internal Medicine, Kyungpook National University College of Medicine, Daegu, South Korea.
Seok-Min KangDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Dong-Ju ChoiDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Byung-Su YooDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea.
Kye Hoon KimDepartment of Cardiovascular Medicine, Chonnam National University Medical School, Gwangju, South Korea.
Byung-Hee OhDepartment of Internal Medicine, Mediplex Sejong Hospital, Incheon, South Korea.
Sang Hong BaekDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Yonsei University · KRSungkyunkwan University · KRChungbuk National University · KRSeoul National University Hospital · KRAsan Medical Center · KRCatholic University of Korea · KRChonnam National University Hospital · KRKyungpook National University · KRSejong General Hospital · KRSeoul National University Bundang Hospital · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRUlsan College · KRUniversity of Ulsan · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Randomized clinical trials of spironolactone showed significant mortality reduction in patients with heart failure with reduced ejection fraction. However, its role in acute heart failure syndrome (AHFS) is largely unknown. Aim: To investigate the prescription characteristics, efficacy and safety of spironolactone in real-world patients with AHFS. Methods: 5,136 AHFS patients who survived to hospital discharge using a nationwide prospective registry in Korea were analyzed. The primary efficacy outcome was 3-year all-cause mortality. Results: Spironolactone was prescribed in 2,402 (46.8%) at discharge: <25 mg in 890 patients (37.1%), ≥25 mg, and <50 mg in 1,154 patients (48.0%), and ≥50 mg in 358 patients (14.9%). Patients treated with spironolactone had a lower proportion of chronic renal failure and renal replacement therapy during hospitalization and had lower serum creatinine level than those who did not. In overall patients, 3-year mortality was not different in both groups (35.9 vs. 34.5%, Conclusions: Although spironolactone was frequently used at lower doses in real-world practice, use of spironolactone significantly reduced 3-year mortality in patients with severely reduced LVEF with acceptable safety profile. However, our findings remain prone to various biases and further prospective randomized controlled studies are needed to confirm these findings.

Indexed as

acute heart failure syndromedrug therapymineralocorticoid receptor antagonistsoutcomespironolactone

Identifiers

PMID35274010
PMCPMC8902170
OpenAlexW4212992411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.